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MEDICATION COMPLIANCE AFTER RENAL TRANSPLANTATION1
L u k as B. H ilb ra n d s ,2 A n d ries J. H oitsm a , a n d  R o b e r t  A.P. K o en e
Department ofMedicine} Division of Nephrology, University Hospital Nijmegen, NL-6500 HB Nijmegen, The Netherlands
Noncompliance is known to be an important cause of 
late graft failure after renal transplantation. We inves­
tigated prospectively the degree of compliance with 
immunosuppressive and antihypertensive drugs dur­
ing the first year after renal transplantation by 
monthly pill counts. In addition, we examined 
whether noncompliance was related to a number of 
demographic and clinical variables or to the occur­
rence of rejections. The study population consisted of 
127 patients who were involved in a randomized trial 
comparing cyclosporine monotherapy with azathio- 
prine-prednisone treatment. Average compliance 
rates approximated 100%, although considerable vari­
ability within and between subjects was observed. Us­
ing an arbitrary limit to classify patients as compliers 
or noncompliers, the following frequencies of noncom­
pliance were observed during the study year: cyclo­
sporine, 23%; azathioprine, 13%; prednisone, 23%; 
atenolol, 36%; and nifedipine, 32%. Average compli­
1 This study was supported by a research grant from Sandoz, 
Basel, Switzerland.
2 Address correspondence to: Lukas B. Hilbrands, Department of 
Medicine, Division of Nephrology, University Hospital Nijmegen, 
P.O. Box 9101, NL-6500 HB Nijmegen, The Netherlands.
ance scores for all immunosuppressive drugs were su­
perior to those of antihypertensive medication 
(P< 0.001). Except for a better compliance for pred­
nisone in men as compared with women, we found no 
consistent relationship between compliance on the 
one hand and several demographic variables, graft 
function, or quality of life on the other hand. Patients 
who developed one or more acute rejection episodes 
showed a higher degree of under compliance, espe­
cially for prednisone, than patients without rejections 
(P<0.01). Following the occurrence of a rejection epi­
sode, compliance scores improved significantly.
Keeping in mind the limitations of the pill count 
method, we conclude that noncompliance with immu­
nosuppressive drugs is not a huge problem during the 
first year after renal transplantation. However, it is 
likely that noncompliance contributes to a certain 
number of acute rejection episodes.
Noncompliance with the therapeutic regimen is considered 
to be a major cause of graft failure after (organ) transplan­
tation (1-5). Accordingly* efforts to encourage adherence to 
the medical regimen are regarded as an important aspect of 
posttransplant patient management (4,5). However, detailed
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data on the extent of medication noncompliance and on fac­
tors associated with it in renal transplant patients are 
scarcely available.
We examined medication compliance during the first year 
after renal transplantation by use of the pill count method, 
looking for an answer to the following questions: (1) What is 
the extent of noncompliance with immunosuppressive and 
antihypertensive drugs after renal transplantation? (2) Can 
the level of noncompliance be predicted from demographic or 
clinical variables? (3) Does noncompliance increase the inci­
dence of acute rejections? (4) Does the occurrence of an acute 
rejection alter the degree of compliance?
PATIENTS AND METHODS
Patient population. The study population comprised 127 adult 
recipients of a first or second postmortal renal allograft who were 
involved in a prospective randomized trial comparing cyclosporine 
monotherapy with the combination of azathioprine and prednisone 
from 3 months after transplantation. Relevant exclusion criteria for 
that study were: history of psychiatric disease, alcohol abuse, and 
poor knowledge of Dutch language.
Treatment protocol All patients received cyclosporine and pred­
nisone during the first 3 months after transplantation. Patients with 
a functioning graft were then allocated to either cyclosporine mono­
therapy or conversion from cyclosporine to azathioprine. After sur­
gery, cyclosporine was given in a dosage of 12 mg/kg/day, which was 
gradually reduced to 4 mg/kg/day at 3 months after transplantation. 
In patients randomized to receive cyclosporine monotherapy, cyclo­
sporine was continued in the same dosage with adjustments to reach 
trough levels between 100 and 200 ng/ml, and the prednisone dosage 
was tapered to zero in 6 weeks. The prednisone dosage was 25 
mg/day during the first month and 20 mg/day during the second and 
third months after transplantation, In patients allocated to azathio- 
prine-prednisone therapy, azathioprine was given in a dosage of 3 
mg/kg/day and the maintenance dose of prednisone amounted to 10 
mg/day. In the cyclosporine group, prednisone was restarted if more 
than one acute rejection or chronic vascular rejection occurred after 
randomization. The same conditions led to replacement of azathio­
prine by cyclosporine in the azathioprine-prednisone group. In case 
of severe and persistent side effects, attributable to one of the drugs, 
patients were put on the alternative treatment regimen. Hyperten­
sion, defined as diastolic blood pressure above 95 mmHg on three 
consecutive occasions, was treated in a standard way using a 
/3-blocker (atenolol), followed by the successive addition of a calcium- 
antagonist (nifedipine) and a diuretic (chlorthalidone) when neces­
sary.
Data collection. Patients were asked to bring along their medica­
tion boxes once monthly at regular control visits to the outpatient 
clinic, during the first year after transplantation. Counting of re­
maining pills was carried out in the presence of the patient for the 
following medications when applicable: cyclosporine (capsules of 25 
and 100 mg), prednisone (tablets of 5 mg), azathioprine (tablets of 25 
and 50 mg), atenolol (tablets of 25, 50, and 100 mg), and nifedipine 
(slow-release tablets of 10 and 20 mg). The third antihypertensive 
drug, chlorthalidone, was used by a few patients only and data on 
this drug were therefore not analyzed. Hospital stays (during which 
drugs were handed out by nurses) and failures to carry medication to 
the outpatient clinic led to missing counts for one or more intervals 
in a number of patients. In such cases, the pill count following the 
missed one measured the compliance during both intervals together 
(i.e., 2 months instead of 1). The amounts of tablets for which pre­
scriptions were written out (always more than required until the 
next visit) were recorded in the charts, and in case of doubt, addi­
tional information was obtained from the patient’s pharmacy.
Demographic data included information on level of education, 
living situation, and job status. Creatinine clearance as a measure of
graft function was estimated with the formula of Cockcroft and Gault
(6). The diagnosis of acute rejection was made on clinical grounds 
and histologically confirmed in 81% of the cases. Quality of life 
measurements included the Sickness Impact Profile, the Affect Bal­
ance Scale, and the Center of Epidemiological Studies Depression 
Scale (CES-D*), and were performed at 3, 6, and 12 months after 
transplantation, as described elsewhere (7).
Calculations. Data on the counts of different strength formula­
tions of the same drug (cyclosporine and azathioprine) were com­
bined, with the appropriate conversion factors taken into account. 
For example, a surplus of 1 capsule of 100 mg of cyclosporine would 
neutralize a shortage of 4 capsules of 25 mg. To express the degree of 
noncompliance (NC) we used the following three scores:
1. Compliance rate (CR) -
number of tablets taken X 100% 
number of tablets prescribed
2. NC^o = 100 if CR deviates more than 10% (in either direction) 
from 100%; otherwise NC±10 = 0*
3. NC 10 100 if CR is smaller than 90%; otherwise NC_10 = 0.
CR was calculated for each monthly interval, for each quarter of the 
study year, and for the whole year. The monthly scores of N C ^ q and 
NC_10 were averaged for each quarter and the mean of these quarter 
scores gave the NC;t30 and NC_10 figures of the entire year. Separate 
scores for the different drugs were averaged to yield composite scores 
for immunosuppressive drugs, antihypertensive drugs, and all 
drugs, respectively.
Some examples may clarify how to interpret these scores. Suppose 
that in a patient who used cyclosporine, CR for this drug was 85%, 
95%, and 120% during months 1, 2, and 3, respectively. The resulting 
NC±;10 for cyclosporine during the first quarter of the year would 
have been (100 + 0 + 100)/3 = 67. Roughly, such a figure indicates 
that the patient did not stick very well to the prescribed regimen 
during 67% of time. If in this imaginary case the simultaneously 
obtained NC±10 for prednisone was 33, then the composite first- 
quarter score for immunosuppressive drugs would have been (67 + 
33)/2 = 50. Analogous to the interpretation of NC^o, NC_10 was 
used as a measure of the percentage of time during which too little of 
the drug was taken. For immunosuppressive drugs, we expected 
NC_10 in particular to be related to the occurrence of rejection 
episodes.
Finally, a patient was regarded to be noncompliant for a given 
drug if the NC±l0 of the entire study year (i.e., the average of the four 
quarter scores) exceeded 20, or in other words, if the patient did not 
take the drug accurately during more than 20% of time.
Statistical analysis. Unless stated otherwise, data are given as 
means with SD. Proportions were compared with chi-square analysis 
using continuity correction. Unpaired comparisons of data were car­
ried out with Wilcoxon’s rank sum test. Paired comparisons of data 
on different drugs were performed with Wilcoxon’s signed ranks test. 
Correlations were assessed by calculating Spearman’s correlation 
coefficient. All data were analyzed with the SAS system (SAS Insti­
tute Inc., Cary, NC). A P-value smaller than 0.05 was considered 
statistically significant.
RESULTS
Two patients refused to bring their medication with them 
to the outpatient clinic; therefore, the results of these pa­
tients could not be analyzed. Initial analysis of the data 
revealed that a number of patients had very low or unduly 
high values of CR for one or more drugs at some time, while 
their mean values for the complete study period of a year 
closely approximated 100%. We presumed that these findings 
might be the result of accidental inaccuracies in transport of
* Abbreviation: CES-D, Center of Epidemiological Studies Depres­
sion Scale; CR, compliance rate; NC, noncompliance.
916 TRANSPLANTATION Vol. 60, No. 9
Table  1. Numbers of patients who used the various drugs and numbers of these patients in whom one or more pill counts for the
particular drugs were carried out during the four quarters of the study year
1-3 Months 4-6 Months 7-9 Months 1 0 —1 2  Months
Used Counted Used Counted Used Counted Used Counted
Cyclosporine 113 105 68 63 56 51 56 52
Azathioprine 26 14 64 58 61 52 58 52
Prednisone 113 104 112 102 81 68 74 69
Atenolol 85 77 86 80 78 73 72 68
Nifedipine 49 42 58 46 44 38 45 39
the drugs to the hospital in patients who actually were quite 
compliant with their drug regimen, or of errors made in pill 
counting. Therefore, we decided to exclude from analysis 
those patients in whom one or both of the following criteria 
for one or more drugs were met: (a) presence of CR >150% 
and CR <50% at different times for the same drug, (b) CR 
>150% or CR <50% at any time, with whole-year CR for the 
same drug between 95% and 105%. Actually, this could mean 
that we had strong evidence for an inaccuracy in counting for 
only one drug at only one of the 12 monthly pill counts. At the 
same time, the remaining counts for the concerning drug and 
all counts for the other drugs might appear to have been 
carried out correctly. Nevertheless, one apparent mistake in 
counting prompted us to question the reliability of all other 
counts in the same patient and we thus decided to exclude 12
patients from our analysis. Of the remaining 113 patients, 
the mean age was 43±13 years (range 17-65), 62% were 
male, 75% had a first transplant, and the mean time on 
dialysis was 28 ±20 months. Fifty-one percent of the subjects 
had primary school or lower vocational training as their 
highest level of education, 26% had a salaried position, and 
15% were living alone. The 14 patients who were excluded 
from analysis did not differ with regard to these character­
istics. Table 1 summarizes the numbers of patients who were 
using the various study drugs as well as the numbers of 
subjects in whom pill counts were carried out during each 
quarter of the study year.
Extent of noncompliance. Noncompliance scores, as de­
fined above, are given in Table 2. Mean compliance rates 
approximated 100%, suggesting a high degree of compliance
T able 2. Compliance rates and noncompliance scores for the various drugs separately, for the combinations of immunosuppressive and
antihypertensive drugs, and for all drugs together“
1-3 Months 4-6 Months 7-9 Months 10-12 Months 1-12 Months
Cyclosporine
CR (%) 99.2+6.4 98,6±7.0 99.1±4,5 100.1±2.2 98.8±4.9
NC±10 10±25 14±30 9±24 2±11 13 ±24*
NC_10 6±20 11±26 7±18 1±5 8±20c
Azathioprine
CR (%) 101.1±2.7 100.3±6.5 100.0+7.3 100.6±7.5 100,9±6.8
NC±10 4 ±13 5±21 12±24 8±19 8±176
NC_10 0±0 1±8 4±16 3±10 2+7°
Prednisone
CR {%) 99.4±7.2 100.2±8,7 100.4±4.7 100.0±6,4 99.5±4.9
NC±10 10±23 12+27 9±20 8+23 12 ±18
NC_10 5 ±18 -3 1+ to 00 2±10 5+21 6 ±16
Atenolol
CR (%) 99.6±14.8 97,7±14.1 99.4±9,1 99.1+10.1 98.7±7.2
N C -10 16±29 18±32 18+34 16±28 17+20
NC_10 9±20 10 ±24 9±26 8±22 10±16
Nifedipine
CR (%) 96.5±19.0 96.0±17,7 97,1±11.2 96.0± 19.8 95.5±16.9
NC±10 19±36 19±32 14±28 20±35 20±30
NC_10 7±26 16±31 11±26 14±29 14±28
Immunosuppressive drugs
CR (%) 99.5±4.6 99.8±5.7 99.8+4.6 100.0±3.6 99.6±3,3
NC±10 9±16 11±19 10±19 6+13 9 ± l l rf
NC_10 4±11 6±16 5+12 3±10 5±8e
Antihypertensive drugs
CR (%) 100,9±12.3 97.4±1L7 99.1±9.1 98.3±11.9 97.7±9.5
NC±10 18±29 19±30 19±33 17+27 18±20d
NC_10 11±24 11±24 11±26 10±22 10±15e
All drugs
CR (%) 99.9±6.0 99,0±6.9 99.3±4.4 99.4±5.8 99.0±4.3
NC_10 13 ±17 13 ±17 12±18 9+16 12 + 12
NC_10 6±12 8±14 6±14 5±12 7±9
a Results are given for each quarter of the study year as well as for the whole year.
b P<0.05, c’eP<0.01, rfP<0.001 for difference between drugs, or combinations of drugs, that are denoted by the same letter.
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for all drugs. However, as is shown by the frequency distri­
bution of compliance with each drug (Fig. 1, A and B), there 
is some variability between subjects, with significant num­
bers of patients demonstrating underconsumption or over­
consumption according to the whole-year CR values. To get 
an impression of the incidence of persistent nonadherence in 
either direction, we calculated the percentage of patients in 
whom CR was either <90% or >110% for more than 50% of 
time. For each drug, this analysis was confined to patients in 
whom at least 3 pill counts for that particular drug were 
available. For the various drugs, the frequencies of persistent 
underconsumption and overconsumption, respectively, were 
as follows: cyclosporine, 1% and 0%; azathioprine, 0% and 
0%; prednisone, 2% and 1%; atenolol, 4% and 1%; and nife­
dipine, 6% and 0%. Differences in compliance rates a t the 
various visits of one subject (intrasubject variability) were 
reflected in the following mean coefficients of variation of CR 
(defined as SD divided by the mean times 100%): cyclospo­
rine, 5.5%; azathioprine, 5.8%; prednisone, 7,2%; atenolol, 
10.8%; and nifedipine, 11.8%. The paradoxical concurrence of 
NC±10 (and NC_10) scores that substantially deviated from 
zero and CR scores near 100% (Table 2) is another manifes­
tation of these observed between-subject and intrasubject 
variabilities. Using an arbitrary level for NC±10 of 20 to 
classify patients as compliers or noncompliers led to the 
following frequencies of noncompliance during the study 
year: cyclosporine, 23%; azathioprine, 13%; prednisone, 23%;
A  Frequency (% ) 
50
40
30
20
10
0
Cyclosporine
“*■ Azathioprine 
Prednisone
I 1 "»■ I T--r T T
40 60 80 100 120 140 160
Compliance Rate (% )
B Frequency (% )
50
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0
Atenolol
-■‘Nifedipine
0
■ f  ■ I
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Compliance Rate (% )
Figure 1. Frequency distributions of compliance rates (number of 
tablets taken as a percentage of number of tablets prescribed) with. 
(A) immunosuppressive and (B) antihypertensive drugs. The compli­
ance rates concern the entire study period (1 year).
atenolol, 36%; and nifedipine, 32%. Except for a tendency 
toward lower NC±10 and NC_10 scores for cyclosporine to­
ward the end of the year, there were no apparent changes in 
time. Mutual (paired) comparisons of the results for the three 
immunosuppressive drugs showed significant differences be­
tween cyclosporine and azathioprine for overall NC±10 and 
NC„10 scores (Table 2). In addition, scores for the combina­
tion of immunosuppressive drugs were more favorable than 
those for the combination of antihypertensive drugs. There 
was a weak correlation between the N C ^o scores for immu­
nosuppressive and antihypertensive drugs (R=0.30, P<0.05) 
only during the fourth quarter of the year. Scores for patients 
randomized to cyclosporine monotherapy were not different 
from those for patients allocated to azathioprine-prednisone 
treatment.
Factors associated with compliance. We investigated 
whether the degree of compliance was related to demo­
graphic characteristics, graft function, or results of quality of 
life measurements (performed in 108 patients). The NC±10 
scores for the immunosuppressive drugs (separately and 
combined) were chosen as outcome variables on the following 
grounds. First, opposite to antihypertensive therapy, immu­
nosuppressive medication was used by all patients. More­
over, generally worse noncompliance scores for antihyperten­
sive drugs would selectively affect overall drug scores in the 
subset of hypertensive patients. Finally, we considered the 
scores for the immunosuppressive drugs to be the most rel­
evant from a clinical point of view. Explanatory variables 
that remained essentially unchanged during the study period 
were distinguished from those that could vary in time. The 
following explanatory variables were assumed to be constant: 
gender, age, level of education, employment status, living 
situation, and number of graft (first or second). Because a 
scatterplot of noncompliance scores versus age showed a 
U-shaped distribution, age was categorized into two addi­
tional variables, one indicating whether age was below or 
above the 25th percentile of the entire group (29 years) and 
the other indicating whether age was below or above the 75th 
percentile (54 years). Correlation analysis revealed a signif­
icant correlation between overall NC±10 for prednisone and 
gender (P<0.05). Accordingly, NC-^q for prednisone was 
higher in women than in men (16±21 vs. 9 ±16, P<0.05). No 
other correlations between demographic variables or graft 
number on the one hand and noncompliance scores on the 
other hand were found. To examine the impact of quality of 
life indices and graft function on noncompliance scores, two 
methodological items had to be dealt with. First, by eliciting 
a rejection episode, noncompliance with immunosuppressive 
drugs might be related to quality of life and graft function in 
reverse direction. Therefore, we excluded patients with one 
or more rejection episodes from this part of the analysis. 
Second, since these explanatory variables varied in time, we 
looked for a correlation of quality of life parameters and graft 
function (assessed at 3, 6, and 12 months after transplanta­
tion) with noncompliance scores obtained during the preced­
ing or following quarter of the year. The combined NC±10 for 
immunosuppressive drugs during the second quarter of the 
year was correlated with the CES-D score at 3 months after 
transplantation. Somewhat unexpectedly, patients in a more 
depressive state had a better compliance score (R=0.38, 
P<0.01). Furthermore, the combined NC±10 for immunosup­
pressive drugs during the third quarter was more unfavor-
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able in patients with higher Sickness Impact Profile scores 
(indicating worse quality of life) a t 6 months after transplan­
tation (R=0.36, P<0.01). We found no significant relation­
ship between graft function and the degree of compliance at 
any time.
Relationship between noncompliance and subsequent rejec­
tion episodes. Noncompliance scores for immunosuppressive 
drugs were compared in 57 patients with and 56 patients 
without one or more acute rejection episodes during the first 
year after transplantation. Since the occurrence of a rejection 
itself appeared to affect compliance (see below), noncompli­
ance scores in rejecting patients were calculated up to and 
including the quarter of the year during which the first 
rejection episode occurred. The means of the available quar­
ter scores resulted in the overall values which are given in 
Table 3. Patients who developed an acute rejection showed a 
worse degree of compliance with a higher incidence of under­
consumption, especially of prednisone. Two patients lost 
their graft due to irreversible rejection. One of these patients 
was clearly noncompliant on the basis of the pill count results 
(mean NCL10 [NCL10]: cyclosporine, 100 [100]; azathioprine,
0 tO]; prednisone, 100 [100]), while the other appeared to 
adhere well to the treatm ent regimen (mean NC^o [NC_10]: 
cyclosporine, 0 [0]; prednisone, 0.5 [0]).
Effect of experiencing a rejection on compliance. To exam­
ine the influence of being faced with a rejection episode on 
compliance behavior, patients who had their first rejection 
episode during the first month after transplantation (n=17) 
were excluded because pill counts before rejection had oc­
curred were obviously not available. Figure 2 shows the time 
course of NC±10 (combined score for all drugs) during the 3 
months before and 3 months after the month during which a 
first acute rejection episode occurred. There was a deteriora­
tion of compliance just before the occurrence of rejection. 
Notably, this was followed by a return of noncompliance 
scores to baseline levels. When mean scores of the 2 months 
before and 2 months after the month with rejection were 
compared, there was a borderline significant change in 
NC-j-io (19±19 vs. 13±22, P —0.05), while NC__10 improved 
substantially (12±18 vs, 6± 20,P < 0.01). The course of com-
Table 3. Compliance rates and noncompliance scores for patients 
with and without one or more acute rejection episodes
^1 Rejection 
(n—57)
No rejection
(n=56) P
Cyclosporine
CR (%) 99.0±4.7 98,7±5.1 NS
NC±10 15 ±24 11±23 NS
NC„10 9±22 7 ±18 NS
Azathioprine
CR (%) 100.4±5.2 101.3±8.0 NS
N C±10 9±14 11 ±23 NS
NC_10 3±9 1±4 NS
Prednisone
CR (%) 98.7±6.0 100.3±3.3 NS
NC±10 15±21 8±14 <0.05
NC_10 10±20 3±9 <0.01
All immunosuppressive drugs
CR (%) 99.2±3.4 99.9±3.2 NS
11±11 7±11 <0.05
NC_10 7±1Q 3±5 <0.01
30
20
10
0
F igure 2. Noncompliance scores for all drugs (NC±10; see text for 
calculation) from 3 months before until 3 months after the month 
during which an acute rejection episode occurred. Data are given as 
means with SEM. The numbers within the bars denote the numbers 
of patients in whom pill counts could be carried out.
pliance scores was similar in patients with and without sub­
sequent rejection episodes (data not shown).
DISCUSSION
The importance of medication compliance after organ 
transplantation is beyond dispute. Several authors have 
demonstrated noncompliance to be a major determinant of 
late graft failure U ,3, <5). Usually, medication noncompliance 
was documented by the finding of low cyclosporine levels U, 
9), or by information on drug-taking behavior provided by the 
patient or family members (I, 5, 8). Sometimes medication 
compliance and compliance with the follow-up regimen were 
considered together (£), and in one study, a definition of 
compliance was lacking (3). All of these, mostly retrospective, 
studies have in common that noncompliance is treated as a 
yes or no phenomenon. In reality, different patterns and 
degrees of noncompliance can be observed (10). In addition, 
studies using information provided by the patient may have 
been subject to recall bias, with patients in whom a rejection 
episode had occurred being more likely to report noncompli­
ance.
The current prospective investigation used the pill count 
method to assess compliance. It provided quantitative infor­
mation that enabled us to express compliance on a numerical 
scale. We have to admit, however, that this technique has its 
limitations too (11). Comparison of a sophisticated compli­
ance-monitoring device with the standard pill count in hy­
pertensive patients demonstrated substantial overestima­
tion by the latter method (12). Tablet counts do not provide 
information about the pattern of day-to-day drug intake, nor 
will they reveal whether some or all of the tablets were not 
taken but discarded. Apparent compliance rates > 100% may 
indicate that patients took more than they were supposed to 
take (either on purpose or by mistake), but may also result 
from the loss of tablets. Finally, the pill count method is 
subject to possible errors being made by the person who 
counts the pills. As reported by others (13), our data show 
that near-optimal average compliance rates may mask con­
siderable variability within and between subjects. Since it 
has been demonstrated that compliance may just as well be 
poor when an excessive number of tablets seems to have been
NC ±10
time from acute rejection (months)
taken {14), we used the frequency of counts yielding devia­
tions from the prescribed amount of at least 10% in either 
direction as one of our outcome measures.
On the whole, our results indicate a high degree of compli­
ance during the first year after renal transplantation. Defin­
ing compliance arbitrarily as adhering to the prescribed reg­
imen at least 80% of the time, the incidence of noncompliance 
ranged from 13% to 36% for the various drugs. These figures 
compare quite favorably with those reported earlier in stud­
ies on antihypertensive and other types of drugs (12, 15). 
Factors that are known to be associated with medication 
compliance include the type of condition or disease, proper­
ties of the treatment regimen, such as side effects, and de­
mographic as well as psychological patient characteristics 
(16). Knowledge of the fact that strict adherence is required 
to prevent graft rejection probably encouraged compliance in 
our patients. Accordingly, immunosuppressive drugs were 
more accurately taken than antihypertensive drugs, despite 
probably being more feared for their adverse effects. Several 
features of our study design may have contributed to the 
observed degree of compliance. First, more compliant behav­
ior in response to repetitive pill counts can easily be imag­
ined. Second, failure to carry medication to the outpatient 
clinic, resulting in missing values, may have occurred more 
often in noncompliant patients. Likewise, the exclusion of 
patients with a history of substance abuse or psychiatric 
disease potentially introduced some selection bias.
With regard to the treatment regimen as a determinant of 
compliance, frequent changes in the dosage of the drugs may 
have influenced compliance negatively. In this respect, a 
distinction between understanding the regimen and follow­
ing the regimen would have been helpful. Of the three im­
munosuppressive drugs, azathioprine ranked higher on the 
scale of compliance than the others, with the difference with 
cyclosporine being statistically significant. Poorer compli­
ance with cyclosporine may be caused by side effects, as well 
as by the size, taste, and daily amounts of the capsules. The 
use of prednisone is generally feared because of its wide 
array of adverse effects.
Demographic factors that have been reported to influence 
compliance after renal transplantation include race, gender, 
age, socioeconomic level, and employment status (1, 3, 9, 17). 
We found only slightly lower levels of compliance with pred­
nisone in female patients. A challenging issue was to exam­
ine the association between medication compliance and qual­
ity of life, which was assessed three times during the study 
period by means of interviews using three instruments. We 
were not able to demonstrate a consistent relationship be­
tween perceived quality of life and compliance scores, al­
though some weak correlations emerged. To our surprise, 
and opposite to data from others (9), patients who were more 
depressed at 3 months after transplantation, as measured 
with the CES-D scale, tended to be more compliant with 
immunosuppressive drugs during the following quarter of 
the study year. Furthermore, patients in whom the Sickness 
Impact Profile indicated a better quality of life at 6 months 
after transplantation showed a higher degree of compliance 
with immunosuppressive drugs during the following months. 
The impact of quality of life on medication compliance has 
been put forward before (9,18,19) and is especially interest­
ing in light of our data on the varying influence of immuno­
suppressive drug regimens on quality of life (7). Taken
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together, it can be speculated that different immunosuppres­
sive drug therapies may vary in their effect on graft survival 
because they have a different effect on quality of life and thus 
on compliance.
Patients experiencing one or more acute rejection episodes 
during the first year after transplantation had worse compli­
ance levels for immunosuppressive drugs, especially pred­
nisone, prior to the occurrence of the first rejection episode. 
This finding indicates that the established relationship be­
tween noncompliance and late graft failure may originate at 
an early stage after transplantation. The current data do not 
allow inferences on an association between early and late 
non compliance. It seems reasonable that such a connection 
exists. On the other hand, it can be argued that early non- 
compliance is related mainly to side effects and their effect on 
quality of life, while late noncompliance just as well may 
occur in patients who are feeling very well and who become 
convinced that they do not need their drugs anymore.
In the case of acute rejection, compliance scores appeared 
to worsen just before its occurrence. Afterward, however, 
compliance scores immediately returned to baseline levels. 
Experiencing a rejection apparently acted as an incentive to 
restore or enhance adherence with the medical regimen.
Our study had a descriptive character and did not address 
the important issues of how to improve compliance. Strate­
gies to modify noncompliant behavior in renal transplant 
patients have been developed (4 , 5), but proof of their efficacy 
is still awaited.
In summary, using the pill count method, we found a high 
degree of medication compliance during the first year after 
renal transplantation. Patients adhered better to their im­
munosuppressive therapy than to antihypertensive medica­
tion, Poor compliance with prednisone was associated with 
the subsequent occurrence of a rejection episode, which in 
turn appeared to correct noncompliant behavior.
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PRETRANSPLANT STATUS AND PATIENT SURVIVAL
FOLLOWING LIVER TRANSPLANTATION l
D e v in  E . E ckhofp, J ohn D . P irsch , Anthony  M . D ’Al e ssa n d r o , S tuart  J. K n ec h tl e , 
C arlton  J. Y o ung , S tuart R. Geffner , F olkert 0 .  B elzer , a n d  M u n c i Kalayoglu2
Department of Surgery} University of Wisconsin School of Medicine, Madison, Wisconsin 53792
The current liver allocation system has been criti­
cized, since available organs go to those who are the 
most critically ill. These recipients have the poorest 
overall survival. Identification of pretransplant risk  
factors for m ortality w ould allow better allocation of 
donor livers. This study w as a retrospective analysis of 
pretransplant clin ical and laboratory parameters and 
subsequent postoperative liver transplant mortality 
to identity high-risk subgroups.
Of 347 consecutive consecutive primary liver trans­
plant recipients, 59 (17%) m et United Network for Or­
gan Sharing (UNOS) criteria for status 4. Pretrans­
plant factors included liver function, coagulation, 
albumin and ammonia levels, renal function, the pres­
ence of ascites, and etiology of liver disease. Overall 
1-year patient survival w as significantly worse for the 
status 4 recipients (89.0% vs. 67.7%; P = 0.01).
In a univariate analysis o f pre transplant risk factors 
for all recipients, elevated creatinine (P=0.008) and 
ammonia (P=0.009), and UNOS status 4 (P=0.01) sig­
nificantly affected postoperative survival. In multiva­
riate analysis of pretransplant risk factors for all re­
1 This paper was presented at the 20th Annual Scientific Meeting 
of the American Society of Transplant Surgeons, May 18-20, 1994.
2 Address correspondence to: Munci Kalayoglu, MD, Department 
of Surgery, H4/780 Clinical Science Center, 600 Highland Avenue, 
Madison, WI 53792-7375.
cipients, elevated creatinine (P=0.003) was the only 
factor to significantly affect postoperative survival. In 
UNOS status 4 patients, univariate analysis of pre- 
transplant risk factors and their influence on patient 
survival demonstrated that prolonged coagulation  
partial thromboplastin time (P=0.04) and a higher 
grade of encephalopathy (P=0.02) significantly af­
fected postoperative survival. Advanced encephalopa­
thy (P=0.009) and prolonged partial thromboplastin 
time (P=0.01) were the only significant risk factors by 
multivariate analysis in status 4 patients.
In status 4 and non-status 4 patients, we identified  
risk factors that adversely affected patient survival, 
but their predictive power was insufficient to deny 
transplantation. Despite the higher mortality in status 
4 recipients, their long-term survival is only slightly  
worse than that of non-status 4 patients. Until better 
predictors of survival are ascertained, our data do not 
support lim iting the use of donor livers in UNOS sta­
tus 4 recipients.
Ortho topic liver transplantation has become the treatment 
of choice for selected patients with advanced liver disease. 
The improved success of liver transplantation has been at­
tributed to refinements in surgical technique, use of veno- 
venous bypass* new immunosuppressive protocols, and 
improved postoperative management (1-4). However, limita-
i\>%
